-
Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform
•
Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of MaxCyte, Inc.’s cGMP compliant ExPERT GTx flow electroporation technology platform, marking it as the first Contract Development and Manufacturing Organization (CDMO) in China to be equipped with this advanced system. The ExPERT GTx platform is…
-
Porton Biologics and SAFE Collaborate to Accelerate Pharmaceutical R&D Services
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy of Sciences (CAS) in 2016, Suzhou Institute of Materia Medica, Clinical Service Center, and SPD BANK.…
-
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Kunshi Biotechnology (Shenzhen) Co., Ltd. The collaboration aims to expedite the Investigational New Drug (IND) filing for Kunshi’s drug candidate RR-M01, marking a significant step forward in the development of third-generation…
-
Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with US biotech company BioMap, an AI-based drug discovery platform co-founded by Baidu’s CEO Robin Li and Baidu Ventures CEO Wei Liu. This collaboration aims to develop an AAV assembly efficiency model…
-
Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline
•
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm BRL Medicine Inc. The collaboration aims to deepen their involvement in the gene and cell therapy (GCT) pipeline, enhance clinical studies, and expedite the commercialization of novel therapies. BRL Medicine’s…
